Philip Morris International (NYSE:PM) Releases Q3 2026 Earnings Guidance

Posted by Brian Himes on Sep 10th, 2026

Philip Morris International (NYSE:PM – Get Free Report) updated its third quarter 2026 earnings guidance on Thursday. The company provided EPS guidance of 2.290-2.340 for the period, compared to the consensus earnings per share estimate of 2.250. The company issued revenue guidance of -.

Philip Morris International Price Performance

NYSE PM opened at $185.71 on Thursday. The firm has a market capitalization of $289.45 billion, a price-to-earnings ratio of 26.68, a price-to-earnings-growth ratio of 2.37 and a beta of 0.37. The company has a 50 day simple moving average of $188.25 and a 200-day simple moving average of $178.77. Philip Morris International has a 52-week low of $142.11 and a 52-week high of $207.76.

Philip Morris International (NYSE:PM – Get Free Report) last posted its quarterly earnings results on Wednesday, July 22nd. The company reported $2.20 earnings per share for the quarter, topping analysts’ consensus estimates of $2.05 by $0.15. The business had revenue of $11.19 billion for the quarter, compared to the consensus estimate of $10.60 billion. Philip Morris International had a net margin of 11.06% and a negative return on equity of 163.41%. Philip Morris International’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period in the prior year, the business posted $1.89 earnings per share. Philip Morris International has set its Q3 2026 guidance at 2.200-2.25 EPS. On average, analysts predict that Philip Morris International will post 8.39 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on PM. Morgan Stanley lifted their price objective on shares of Philip Morris International from $200.00 to $215.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Barclays upped their price target on Philip Morris International from $205.00 to $225.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Stifel Nicolaus boosted their target price on Philip Morris International from $195.00 to $205.00 and gave the stock a “buy” rating in a report on Thursday, July 23rd. BTIG Research set a $221.00 price target on shares of Philip Morris International and gave the company a “buy” rating in a research report on Friday, July 24th. Finally, Bank of America reaffirmed a “buy” rating on shares of Philip Morris International in a report on Thursday, May 21st. Ten research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $205.89.

Read Our Latest Stock Analysis on Philip Morris International

Philip Morris International News Roundup

Here are the key news stories impacting Philip Morris International this week:

Positive Sentiment: Higher 2026 earnings outlook: Philip Morris raised its 2026 adjusted diluted EPS forecast to $8.35-$8.50, with the increase attributed to currency tailwinds rather than a change to its underlying operational outlook. The guidance supports investor confidence and is above the company’s previous expectations. Philip Morris Raises 2026 Earnings Guidance Amid Currency Tailwinds
Positive Sentiment: ZYN portfolio expansion: PMI’s U.S. business is broadening ZYN with new 1.5 mg and 8 mg strengths, the higher-moisture ZYN ULTRA line, additional flavors and formats, and more pouches per can. The expanded range could attract more legal-age adult nicotine consumers and support volume growth. PMI U.S. Expands ZYN Portfolio to Offer Adults More Smoke-Free Choices
Positive Sentiment: Regulatory support for nicotine pouches: FDA authorization for 11 ZYN products, including higher-strength ZYN ULTRA offerings, strengthens PMI’s position in the fast-growing U.S. nicotine-pouch market and provides a foundation for scaling production after substantial manufacturing investments. FDA Authorization Expands Philip Morris’s Zyn Bet, Can It Pay Off?
Neutral Sentiment: Execution remains important: The ZYN rollout is strategically favorable, but the earnings benefit will depend on consumer adoption, manufacturing capacity and the company’s ability to convert product expansion into sustainable sales and profit growth.

Institutional Investors Weigh In On Philip Morris International

Several hedge funds have recently made changes to their positions in PM. Safe Harbor Fiduciary LLC acquired a new stake in Philip Morris International during the fourth quarter worth about $29,000. Measured Wealth Private Client Group LLC bought a new stake in shares of Philip Morris International during the third quarter valued at approximately $32,000. McIlrath & Eck LLC acquired a new position in shares of Philip Morris International in the second quarter valued at $36,000. Swiss RE Ltd. acquired a new position in shares of Philip Morris International in the fourth quarter valued at $40,000. Finally, WFA of San Diego LLC bought a new position in Philip Morris International in the second quarter worth $41,000. Institutional investors own 78.63% of the company’s stock.

Philip Morris International Company Profile

(Get Free Report)

Philip Morris International Inc is a global tobacco and nicotine company headquartered in Stamford, Connecticut. The company develops, manufactures and markets cigarettes, smoke-free products, nicotine products and related consumer offerings in markets around the world.

Its portfolio includes internationally recognized cigarette brands such as Marlboro, Parliament, L&M and Chesterfield. PMI is also expanding beyond traditional cigarettes through heated-tobacco products, including IQOS, e-vapor products such as VEEV, and oral nicotine products including ZYN, which became part of the company’s portfolio following its acquisition of Swedish Match.

Philip Morris International was established as an independent company in 2008 after being separated from Altria Group, whose U.S.